STOCK TITAN

Edgewise Therapeutics, Inc. - EWTX STOCK NEWS

Welcome to our dedicated page for Edgewise Therapeutics news (Ticker: EWTX), a resource for investors and traders seeking the latest updates and insights on Edgewise Therapeutics stock.

Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is a biotechnology company dedicated to the development of novel therapies for severe, rare muscle disorders. Headquartered in Boulder, Colorado, the company is renowned for its innovative approach to treating diseases involving skeletal muscle. Founded with Series A financing from OrbiMed, Edgewise Therapeutics is focused on the discovery, development, and commercialization of orally bioavailable, small molecule therapies designed to address musculoskeletal diseases.

The core mission of Edgewise Therapeutics is to transform the lives of patients suffering from debilitating muscle conditions. The company’s clinical-stage biopharmaceutical expertise is reflected in its robust pipeline of potential treatments, which aim to offer improved patient outcomes and enhanced quality of life.

Among its current projects, Edgewise Therapeutics is working on several promising candidates that target specific muscle-related conditions. By leveraging advanced research methodologies and cutting-edge technology, the company is able to create therapies that are not only effective but also accessible to a broader patient population.

Financially, Edgewise Therapeutics is well-positioned with strong backing from investors and strategic partners. The company continues to achieve significant milestones in its development programs, further solidifying its reputation as a leader in the biopharmaceutical landscape.

In recent news, Edgewise Therapeutics has made noteworthy progress with its clinical trials and has expanded its research partnerships to expedite the development of its drug candidates. The latest developments underline the company's commitment to innovation and excellence in the field of muscle disease therapeutics.

  • Location: Boulder, Colorado
  • Core Focus: Novel therapies for rare muscle disorders
  • Key Projects: Orally bioavailable small molecule therapies
  • Partnerships: Supported by OrbiMed and other strategic investors
Rhea-AI Summary

Edgewise Therapeutics (EWTX) has initiated the LYNX Phase 2 clinical trial for EDG-5506 in children with Duchenne muscular dystrophy (DMD) at Rare Disease Research in Atlanta, Georgia. The trial aims to evaluate safety, pharmacokinetics, and biomarkers of muscle damage over 12 weeks, followed by a 9-month open-label phase. Approximately 27 children aged 4 to 9 will be enrolled. EDG-5506, a novel myosin modulator, shows promise based on previous studies. Edgewise will host webinars in November to discuss the trial with the community.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.07%
Tags
-
Rhea-AI Summary

Edgewise Therapeutics (NASDAQ: EWTX) announced positive interim results from its ongoing ARCH study, focusing on the safety and efficacy of EDG-5506 in adults with Becker Muscular Dystrophy (BMD). Key findings include a significant 39% reduction in serum creatine kinase and a 75% drop in fast skeletal muscle troponin I, indicating reduced muscle damage. Improved North Star Ambulatory Assessment (NSAA) scores were also reported, with eight out of twelve participants showing functional improvement. EDG-5506 continues to be well-tolerated at increased doses, supporting its potential to alter BMD disease progression.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.53%
Tags
none
-
Rhea-AI Summary

Edgewise Therapeutics (EWTX) will host a symposium at the 27th International Hybrid Annual Congress of the World Muscle Society in Halifax, Nova Scotia, from October 11-15, 2022. The event will feature the presentation of 6-month interim results from the ARCH study on EDG-5506, an investigational therapy for Becker Muscular Dystrophy. This therapy targets fast skeletal muscle fibers to reduce damage. Key opinion leaders will discuss related topics. The symposium is accessible only to registered attendees and will also be streamed online.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.94%
Tags
conferences
Rhea-AI Summary

Edgewise Therapeutics, Inc. (NASDAQ: EWTX) has successfully closed an upsized public offering of 13,372,093 shares at a price of $10.32 per share, yielding total gross proceeds of $138 million. This offering was led by J.P. Morgan and SVB Securities as joint book-running managers. The registration statement for the offering was declared effective by the SEC. This capital infusion supports Edgewise's focus on developing innovative treatments for rare neuromuscular and cardiac disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.89%
Tags
-
Rhea-AI Summary

Edgewise Therapeutics (NASDAQ: EWTX) announced the pricing of an upsized public offering of 11,627,907 shares at $10.32 per share, expected to raise approximately $120 million before expenses. The offering includes an option for underwriters to purchase an additional 1,744,186 shares. The offering will close around September 16, 2022, subject to customary conditions. J.P. Morgan and SVB Securities are the joint book-running managers, with Wedbush PacGrow as the lead manager. The proceeds will support the development of innovative treatments for severe neuromuscular and cardiac disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
-
Rhea-AI Summary

Edgewise Therapeutics (NASDAQ: EWTX) intends to offer and sell $100 million of its common stock in an underwritten public offering. An additional 30-day option for underwriters to purchase up to $15 million of common stock is also included. The offering is subject to market conditions and no assurance can be given regarding its completion or terms. J.P. Morgan and SVB Securities are acting as joint book-running managers. Edgewise focuses on innovative treatments for rare neuromuscular and cardiac disorders, indicating potential growth opportunities with the capital raised.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.01%
Tags
Rhea-AI Summary

Edgewise Therapeutics (NASDAQ: EWTX) announced positive interim results from its ARCH study, focusing on the investigational drug EDG-5506 for Becker muscular dystrophy (BMD). After four months, participants exhibited an average 1.17-point increase in the North Star Ambulatory Assessment (NSAA) and significant reductions in muscle damage biomarkers: serum creatine kinase levels decreased by 29% and fast skeletal muscle troponin I by 74%. EDG-5506 was well-tolerated, with no serious adverse events. A webcast discussing the findings is scheduled for September 12 at 8:30 a.m. ET.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.34%
Tags
none
-
Rhea-AI Summary

Edgewise Therapeutics (NASDAQ: EWTX) announced FDA authorization for the LYNX Phase 2 clinical trial of EDG-5506 in children with Duchenne Muscular Dystrophy (DMD). The trial aims to enroll approximately 27 participants, aged 4 to 9, across the U.S. to assess safety and efficacy over 12 weeks. EDG-5506, previously successful in BMD trials, is designed to mitigate muscle damage. Positive feedback from patient advocacy groups underscores the significance of expanding treatment options for DMD patients, a condition affecting 12,000-15,000 in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.29%
Tags
-
Rhea-AI Summary

Edgewise Therapeutics announced positive interim results for its EDG-5506 treatment in Becker muscular dystrophy (BMD) from the ARCH study. The ongoing trial indicates a significant reduction in muscle damage biomarkers, with creatine kinase and troponin I decreasing by 30% and 68%, respectively, after two months. The company has initiated Phase 2 trials for both BMD and plans for Duchenne muscular dystrophy (DMD) later in 2022. Financially, as of June 30, 2022, Edgewise reported $248.4 million in cash, expected to sustain operations through 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.33%
Tags
Rhea-AI Summary

Edgewise Therapeutics (NASDAQ: EWTX) has announced that its senior management will participate in the virtual 2022 Wedbush PacGrow Healthcare Conference on August 9-10. The company is focused on developing therapies for rare muscle disorders. A live panel discussion titled “Muscle Beach” is scheduled for August 9 at 2:20 pm ET and will be available for replay. Edgewise employs a unique drug discovery platform aimed at treating severe neuromuscular and cardiac disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.78%
Tags
conferences

FAQ

What is the current stock price of Edgewise Therapeutics (EWTX)?

The current stock price of Edgewise Therapeutics (EWTX) is $30.78 as of December 20, 2024.

What is the market cap of Edgewise Therapeutics (EWTX)?

The market cap of Edgewise Therapeutics (EWTX) is approximately 3.0B.

What is Edgewise Therapeutics, Inc.?

Edgewise Therapeutics, Inc. is a biotechnology company focused on developing novel therapies for severe, rare muscle disorders.

Where is Edgewise Therapeutics located?

Edgewise Therapeutics is headquartered in Boulder, Colorado.

What is the core focus of Edgewise Therapeutics?

The company focuses on the discovery, development, and commercialization of treatments for musculoskeletal diseases.

What are Edgewise Therapeutics' key projects?

Its key projects involve developing orally bioavailable, small molecule therapies for rare muscle disorders.

Who financed Edgewise Therapeutics' Series A round?

The company's Series A financing was provided by OrbiMed.

Is Edgewise Therapeutics a public company?

Yes, Edgewise Therapeutics is a public company listed on NASDAQ under the symbol EWTX.

What recent achievements has Edgewise Therapeutics made?

The company has made significant progress in its clinical trials and expanded its research partnerships.

What kind of diseases is Edgewise Therapeutics targeting?

Edgewise Therapeutics targets severe, rare muscle disorders involving skeletal muscle.

What type of therapies is Edgewise Therapeutics developing?

The company is developing orally bioavailable, small molecule therapies.

What makes Edgewise Therapeutics' treatments innovative?

Their treatments aim to offer improved patient outcomes and enhanced quality of life by leveraging advanced research methodologies and cutting-edge technology.

Edgewise Therapeutics, Inc.

Nasdaq:EWTX

EWTX Rankings

EWTX Stock Data

3.00B
73.99M
0.47%
111.61%
6.75%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BOULDER